Phase 3 study of ceftaroline versus ceftriaxone plus adjunctive clarithromycin in adults with community-acquired pneumonia

Phase 3, randomised, double-blind trial of ceftaroline fosamil, ceftriaxone and clarithromycin in community-acquired pneumonia (CAP) (2 arms), sponsored by Cerexa. Primary endpoints: Clinical cure rate at test-of-cure in clinically evaluable population and Clinical cure rate at test-of-cure in modified intent-to-treat efficacy population. Started Oct 2007; status: completed.